Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| BB Biotech AG earns after-tax profits of CHF 717 million in the first half-year 2015 | ||
| By: Nasdaq / GlobeNewswire - 07 Jul 2015 | Back to overview list |
|
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its profits in the first half-year 2015. Based on preliminary unaudited consolidated results, BB Biotech AG closed the past half-year with a profit of CHF 717 million (CHF 261 million in the corresponding period of the previous year). The net profit figure for the first half-year 2015 reflects the fundamental strength of the biotech sector and the successful investment strategy pursued by BB Biotech with clearly defined areas of focus. BB Biotech's share price rose 21.5% in CHF respectively 38.7% in EUR during the half-year period. The half-year report for 2015 will be published on July 17, 2015.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.7 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science. Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 1.2 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: BB BIOTECH AG via GlobeNewswire
HUG#1935156
|
||
|
||
 | Back to overview list | |